Your browser doesn't support javascript.
loading
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
Blondiaux, Nicolas; Moune, Martin; Desroses, Matthieu; Frita, Rosangela; Flipo, Marion; Mathys, Vanessa; Soetaert, Karine; Kiass, Mehdi; Delorme, Vincent; Djaout, Kamel; Trebosc, Vincent; Kemmer, Christian; Wintjens, René; Wohlkönig, Alexandre; Antoine, Rudy; Huot, Ludovic; Hot, David; Coscolla, Mireia; Feldmann, Julia; Gagneux, Sebastien; Locht, Camille; Brodin, Priscille; Gitzinger, Marc; Déprez, Benoit; Willand, Nicolas; Baulard, Alain R.
Afiliação
  • Blondiaux N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Moune M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Desroses M; Université Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France.
  • Frita R; Division of Translational Medicine and Chemical Biology, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Flipo M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Mathys V; Université Lille, Inserm, Institut Pasteur de Lille, U1177-Drugs and Molecules for Living Systems, F-59000 Lille, France.
  • Soetaert K; National Reference Center for Tuberculosis and Mycobacteria, Bacterial Diseases Service, Operational Direction Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
  • Kiass M; National Reference Center for Tuberculosis and Mycobacteria, Bacterial Diseases Service, Operational Direction Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
  • Delorme V; National Reference Center for Tuberculosis and Mycobacteria, Bacterial Diseases Service, Operational Direction Communicable and Infectious Diseases, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
  • Djaout K; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Trebosc V; Tuberculosis Research Laboratory, Institut Pasteur Korea, South Korea.
  • Kemmer C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Wintjens R; Bioversys AG, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
  • Wohlkönig A; Biozentrum, University of Basel, Basel, Switzerland.
  • Antoine R; Bioversys AG, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
  • Huot L; Laboratoire des Biopolymères et des Nanomatériaux Supramoléculaires, Université Libre de Bruxelles, Brussels, Belgium.
  • Hot D; VIB Center for Structural Biology, VIB, Pleinlaan 2, 1050 Brussels, Belgium.
  • Coscolla M; Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Pleinlaan 2, 1050 Brussels, Belgium.
  • Feldmann J; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Gagneux S; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Locht C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Brodin P; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Gitzinger M; University of Basel, Basel, Switzerland.
  • Déprez B; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Willand N; University of Basel, Basel, Switzerland.
  • Baulard AR; Swiss Tropical and Public Health Institute, Basel, Switzerland.
Science ; 355(6330): 1206-1211, 2017 Mar 17.
Article em En | MEDLINE | ID: mdl-28302858
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Farmacorresistência Bacteriana Múltipla / Etionamida / Tuberculose Extensivamente Resistente a Medicamentos / Isoxazóis / Mycobacterium tuberculosis / Antituberculosos Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Espiro / Farmacorresistência Bacteriana Múltipla / Etionamida / Tuberculose Extensivamente Resistente a Medicamentos / Isoxazóis / Mycobacterium tuberculosis / Antituberculosos Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article